Sökning: WFRF:(Jackisch Christian) >
Pegylated liposomal...
-
Pujade-Lauraine, EricHôpital Hôtel-Dieu, Paris, France
(författare)
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
- Artikel/kapitelEngelska2010
Förlag, utgivningsår, omfång ...
-
American Society of Clinical Oncology,2010
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-133699
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-133699URI
-
https://doi.org/10.1200/JCO.2009.25.7519DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:120965014URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
PURPOSE: This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC).PATIENTS AND METHODS: Patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum and taxane-based therapies were randomly assigned by stratified blocks to CD (carboplatin area under the curve [AUC] 5 plus PLD 30 mg/m(2)) every 4 weeks or CP (carboplatin AUC 5 plus paclitaxel 175 mg/m(2)) every 3 weeks for at least 6 cycles. Primary end point was progression-free survival (PFS); secondary end points were toxicity, quality of life, and overall survival.RESULTS: Overall 976 patients were recruited. With median follow-up of 22 months, PFS for the CD arm was statistically superior to the CP arm (hazard ratio, 0.821; 95% CI, 0.72 to 0.94; P = .005); median PFS was 11.3 versus 9.4 months, respectively. Although overall survival data are immature for final analysis, we report here a total of 334 deaths. Overall severe nonhematologic toxicity (36.8% v 28.4%; P < .01) leading to early discontinuation (15% v 6%; P < .001) occurred more frequently in the CP arm. More frequent grade 2 or greater alopecia (83.6% v 7%), hypersensitivity reactions (18.8% v 5.6%), and sensory neuropathy (26.9% v 4.9%) were observed in the CP arm; more hand-foot syndrome (grade 2 to 3, 12.0% v 2.2%), nausea (35.2% v 24.2%), and mucositis (grade 2-3, 13.9% v 7%) in the CD arm.CONCLUSION: To our knowledge, this trial is the largest in recurrent ovarian cancer and has demonstrated superiority in PFS and better therapeutic index of CD over standard CP.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Wagner, UwePhilipps University Marburg, Marburg, Germany
(författare)
-
Åvall-Lundqvist, ElisabethKarolinska Institutet(Swepub:liu)eliav51
(författare)
-
Gebski, ValNHMRC Clinical Trials Centre, Sydney, NSW, Australia
(författare)
-
Heywood, MarkBC Cancer Agency, Vancouver, BC, Canada
(författare)
-
Vasey, Paul AWesley Medical Centre, Auchenflower, QLD, Australia
(författare)
-
Volgger, BirgitMedical University Innsbruck, Innsbruck, Austria
(författare)
-
Vergote, IgnaceUniversity Hospital Leuven, Leuven, Belgium
(författare)
-
Pignata, SandroCancer National Institute, Naples, Italy
(författare)
-
Ferrero, AnnamariaGynecological Oncology Institute for Cancer Research and Treatment (IRCC) of Candiolo & AO Ordine Mauriziano, Turin, Italy
(författare)
-
Sehouli, JalidUniversity Hospital Charité, Berlin, Germany
(författare)
-
Lortholary, AlainCentre Catherine De Sienne, Nantes, France
(författare)
-
Kristensen, GunnarNorwegian Radium Hospital, Oslo, Norway
(författare)
-
Jackisch, ChristianKlinikum Offenbach, Offenbach, Germany
(författare)
-
Joly, FlorenceCHU-Centre François Baclesse, Caen, France
(författare)
-
Brown, ChrisNHMRC Clinical Trials Centre, Sydney, NSW, Australia
(författare)
-
Le Fur, NathalieARCAGY-GINECO, Paris, France
(författare)
-
du Bois, AndreasDr Horst Schmidt Klinik, Wiesbaden, Germany
(författare)
-
Hôpital Hôtel-Dieu, Paris, FrancePhilipps University Marburg, Marburg, Germany
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Clinical Oncology: American Society of Clinical Oncology28:20, s. 3323-33290732-183X1527-7755
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Pujade-Lauraine, ...
-
Wagner, Uwe
-
Åvall-Lundqvist, ...
-
Gebski, Val
-
Heywood, Mark
-
Vasey, Paul A
-
visa fler...
-
Volgger, Birgit
-
Vergote, Ignace
-
Pignata, Sandro
-
Ferrero, Annamar ...
-
Sehouli, Jalid
-
Lortholary, Alai ...
-
Kristensen, Gunn ...
-
Jackisch, Christ ...
-
Joly, Florence
-
Brown, Chris
-
Le Fur, Nathalie
-
du Bois, Andreas
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet